
Two more nationally regarded researchers have been recruited to support critical biomedical research in Minnesota, thanks to the Minnesota Partnership for Biotechnology and Medical Genomics. The two faculty investigators have assumed their new positions at Mayo Clinic and the University of Minnesota.
The Minnesota Partnership for Biotechnology and Medical Genomics is awarding $7 million in state-funded infrastructure support to four partnering research teams. The awards will provide equipment and materials for research on congenital heart disease, improved bioinformatics to analyze genomic data, advanced imaging of the brain for numerous diseases and the creation of a crystallization facility to study hundreds of medical conditions at the molecular level.
A production laboratory founded by the Minnesota Partnership has transferred its first potential therapy — a medication for multiple sclerosis — to a processing plant in Minnesota. This step will complete purification of material to fully enable translation from preclinical to clinical development.
Medical scientists in Minnesota are focusing their expertise on a pest that destroys soybeans. The goal of the Minnesota Partnership team is to develop an insecticide that is safe for humans but will kill the soybean aphid, a bug that's been ravaging Minnesota crops.
The Minnesota Partnership for Biotechnology and Medical Genomics is awarding nearly $5.4 million in state–funded research support to six research teams. This new round of scientific exploration will provide initial support for research on cancer, neurological diseases, heart disease, gastrointestinal conditions and nanotechnology that could impact a range of diseases.
| |
Copyright 2003-2009 Mayo Foundation for Medical Education and Research and Regents
of the University of Minnesota. All Rights Reserved.